We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in auto immune disorders. Our lead assets from natural products, have global potential to address the major skin diseases, including psoriasis, atopic dermatitis, Seborrheic Dermatitis, and eczema, which is expected to exceed US$46 billion in aggregate market size by 2029, according to Frost & Sullivan.

For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets and significant unmet global medical needs. Our technical expertise in structure-based drug design and our innovative drug discovery engine have allowed us to develop natural product bases support therapies for psoriasis using plant extracts but also actively developed  small molecules and degrader therapies targeted at anti-microbial proteins  S100, in addition to building next- generation cell signalling inhibitors.

Intellectual property rights are fundamental to our business. Through our robust research and development, we have strategically developed a global intellectual property portfolio with exclusive rights to issued patents or patent applications worldwide with respect to our products and product candidates.